Obermatt
See Similar Stocks →

MaxCyte

NSQ:MXCT · US57777K1060
Life Sciences Tools & ServicesSmall

360

17
Profit price47
Owner Earnings Yield1
Dividend Yield1
Price/Sales67
EV / Gross Profit100
Price/Book58
Return on Capital26
Cash Return on Capital32
Return on Equity40
EBIT Margin10
Gross Profitability30
Accruals65
Owner Earnings Margin12
Sales growth41
Profit growth79
Reinvestment41
Price momentum10
Debt load52
Refinancing97
Debt Payback1
Liquidity16
Analyst ratings18
Opinion Changes50
Price Target Upside100
Market mood40
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MaxCyte doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded1998
Employees107
Websitemaxcyte.com
ISINUS57777K1060
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsStem Cell TherapyBiomedical EngineeringGeneticsBiotechnologyManufacturingMedical Device

Description

MaxCyte, Inc., a commercial cell engineering company, focuses on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to suppor…

Analysis

Middle-of-the-road

MaxCyte, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
54
2023202420252026

All-time high

91

Jan 2023

All-time low

54

Jun 2026

Average rank

75

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
8
5
5
Price/Earnings
57
36
36
36
Price/Book
58
60
55
67
Dividend Yield
1
1
1
1
Value (overall)
60
19
20
25

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MaxCyte with its peers
Cartesian Therapeutics
NMQ:RNAC
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Charles River Laboratories
NYQ:CRL
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →